Immuneering Corp Cl A (IMRX) Stock Price, Quote & News

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8080

Website: immuneering.com

Address:

245 Main Street, Second Floor, Cambridge, United States

dcrown Nov. 14 at 8:42 PM

$IMRX can’t we get a $46 Sanofi offer before end of the year ?

0 · Reply

JH2500 Nov. 14 at 8:25 PM

$IMRX: See that Short Algo bot right under ask...Taking out every buy with a click lower on the ask. Relentless.

1 · Reply

JH2500 Nov. 14 at 8:09 PM

$IMRX: No question headed into below $6 into close...Floor may drop out worse that yesterday on this one and that could be real trouble. All in all, headed significantly lower here.

1 · Reply

JH2500 Nov. 14 at 7:41 PM

$IMRX: Headed below $6 as early as the close today. The pop is over. Now the long wait for any news and the daily decline is in progress.

1 · Reply

D541 Nov. 14 at 6:42 PM

$IMRX Michael Burry shut down his hedge fund today !

0 · Reply

dcrown Nov. 14 at 6:35 PM

$IMRX more likely BO at works , they won’t expand and are in standby mode

1 · Reply

velle Nov. 14 at 6:15 PM

$IMRX blocling this moron @JH2500

0 · Reply

JH2500 Nov. 14 at 6:07 PM

$IMRX: Likely ends the day sub $6. Good stock at $4.20 or so.

0 · Reply

JH2500 Nov. 14 at 4:09 PM

$IMRX: Likely see a close sub $5.60 as week closes. When these plays fall back they keep falling. $4.65 is Support. Almost certainly going there. Sorry but correct.

1 · Reply

Captenotwo Nov. 14 at 3:20 PM

$IMRX JH2500 If your nervous about selling premarket and can’t see where this thing is going over the next few years buy it back. Constant bashing to make yourself feel better looks desperate. Just sayin Cap You may be right in the short term. But long term this stocks gold.

0 · Reply

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 2 days ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 4, 2025, 4:05 PM EST - 10 days ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Sep 29, 2025, 4:37 PM EDT - 6 weeks ago

Immuneering Corporation - Special Call

Sep 26, 2025, 4:01 PM EDT - 7 weeks ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 25, 2025, 2:19 PM EDT - 7 weeks ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 12:08 AM EDT - 7 weeks ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 7 weeks ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:01 PM EDT - 7 weeks ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 16, 2025, 7:00 AM EDT - 2 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 10, 2025, 7:00 AM EDT - 2 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Aug 26, 2025, 4:05 PM EDT - 2 months ago

Immuneering Announces Closing of $25 Million Private Placement

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Aug 21, 2025, 8:00 AM EDT - 3 months ago

Immuneering Announces $25 Million Private Placement

Aug 13, 2025, 4:05 PM EDT - 3 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 9, 2025, 8:00 AM EDT - 4 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jun 17, 2025, 6:00 AM EDT - 5 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 16, 2025, 8:00 AM EDT - 5 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

May 29, 2025, 8:00 AM EDT - 6 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 4:05 PM EDT - 6 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 21, 2025, 4:30 PM EDT - 8 months ago

Immuneering Corporation Announces Grant of Inducement Award

Mar 20, 2025, 4:05 PM EDT - 8 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 8 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Feb 3, 2025, 4:05 PM EST - 10 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 7, 2025, 9:28 AM EST - 11 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Dec 19, 2024, 8:00 AM EST - 11 months ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 13, 2024, 2:10 PM EST - 1 year ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Mar 5, 2024, 5:00 PM EST - 1 year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 8:00 AM EST - 1 year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 8:00 AM EST - 1 year ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Feb 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Announces Participation in February Investor Conferences

Dec 12, 2023, 8:00 AM EST - 2 years ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

dcrown Nov. 14 at 8:42 PM

$IMRX can’t we get a $46 Sanofi offer before end of the year ?

0 · Reply

JH2500 Nov. 14 at 8:25 PM

$IMRX: See that Short Algo bot right under ask...Taking out every buy with a click lower on the ask. Relentless.

1 · Reply

JH2500 Nov. 14 at 8:09 PM

$IMRX: No question headed into below $6 into close...Floor may drop out worse that yesterday on this one and that could be real trouble. All in all, headed significantly lower here.

1 · Reply

JH2500 Nov. 14 at 7:41 PM

$IMRX: Headed below $6 as early as the close today. The pop is over. Now the long wait for any news and the daily decline is in progress.

1 · Reply

D541 Nov. 14 at 6:42 PM

$IMRX Michael Burry shut down his hedge fund today !

0 · Reply

dcrown Nov. 14 at 6:35 PM

$IMRX more likely BO at works , they won’t expand and are in standby mode

1 · Reply

velle Nov. 14 at 6:15 PM

$IMRX blocling this moron @JH2500

0 · Reply

JH2500 Nov. 14 at 6:07 PM

$IMRX: Likely ends the day sub $6. Good stock at $4.20 or so.

0 · Reply

JH2500 Nov. 14 at 4:09 PM

$IMRX: Likely see a close sub $5.60 as week closes. When these plays fall back they keep falling. $4.65 is Support. Almost certainly going there. Sorry but correct.

1 · Reply

Captenotwo Nov. 14 at 3:20 PM

0 · Reply

JH2500 Nov. 14 at 3:16 PM

$IMRX: Headed to $4.65 Support. Not short here but will re-enter long if the $4.65 Support holds. Lets see if it does.

0 · Reply

JH2500 Nov. 14 at 2:51 PM

$IMRX: Dead cat bounce over for Market. Move lower continues. $IMRX Support is $4.65 now. Lets see if it holds.

0 · Reply

D541 Nov. 14 at 2:39 PM

$IMRX

0 · Reply

JH2500 Nov. 14 at 2:03 PM

$IMRX: Sold last of my $IMRX in pre-market...This one will certainly trade much lower as market Correction continues in coming sessions. Best of luck. Buying back lower is the smart move.

0 · Reply

JH2500 Nov. 14 at 1:30 PM

$IMRX: Likely to retest $4.25 Spport in coming sessions. Market going to Correct hard here and buying into a falling knife is foolish.

1 · Reply

TAG01 Nov. 14 at 12:20 PM

$CDTX Good Morning All! got to lovely morning opening ny eys and rolling over to check my portfolio! flashbacks from my first CCXI BO then to PRVB and MYOV now this year VRNA and this! just glad its closing in 2026.. did have a big looser in there of BLUE but cant win them all. however I will track this managment team and Board to where they go. smart people produce good outcomes. just followed CCXI ceo Thomas Schall to $IMRX for a pancreatic cancer treatments that has had good trials and i think is my next 10x bagger. I am in on that for 6.50.

0 · Reply

Bgirl_smirk Nov. 14 at 9:12 AM

$OTLK buy the dips hold and wait $IMRX I traded just like I do this one and it will pay us don’t get scared

0 · Reply

Bgirl_smirk Nov. 14 at 8:30 AM

$IMRX if you played with me months ago come join me in $OTLK we will get 10

0 · Reply

dcrown Nov. 13 at 9:52 PM

$IMRX stop the fkring at the end of the day , not a single drug combined with FOLFIRINOX have done it ; but this

0 · Reply

rekc Nov. 13 at 9:10 PM

$IMRX As Warren Buffett has famously said "When a stock goes down for no reason, watch out below."

1 · Reply

dcrown Nov. 13 at 8:41 PM

$IMRX Sanofi to move

0 · Reply

Captenotwo Nov. 13 at 8:31 PM

$IMRX Bought 2000 more. I have a fever! Cap

0 · Reply

Market Cap	275.19M
Revenue (ttm)	0.00
Net Income (ttm)	-61.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,299,999
Avg Vol	2,157,000
Day's Range	N/A - N/A
Shares Out	41.57M
Stochastic %K	55%
Beta	0.46
Analysts	Strong Sell
Price Target	$16.67